SOBI Agrees to Acquire Arthrosi Therapeutics

Swedish Orphan Biovitrum (SOBI) has reached an agreement to acquire Arthrosi Therapeutics Inc., a late-stage biotechnology company developing a highly potent and selective next-generation URAT1 inhibitor. This drug is intended to reduce serum urate (sUA) levels, mitigate flares, and dissolve tophi in patients with gout and tophaceous gout.

The total transaction value is estimated to be up to $1.5 billion, which comprises an upfront payment of $950 millionupon closing (subject to customary adjustments) and contingent consideration of up to $550 million. The acquisition is anticipated to close in the first half of 2026.

The acquisition strengthens SOBI’s gout treatment franchise by integrating pozdeutinurad (AR882). This investigational, once-daily oral URAT1 inhibitor is currently being evaluated in two fully enrolled global Phase 3 clinical studies for the potential management of progressive and tophaceous gout, with data expected to read out in 2026.

Pozdeutinurad has the potential to become the preferred therapy for patients with progressive gout whose persistent symptoms remain unresolved by first-line treatment. SOBI leadership believes the product has the capacity to materially accelerate the company’s growth through the mid-2030s and beyond.

Arthrosi Therapeutics expressed enthusiasm about joining forces with SOBI, trusting that SOBI’s global commercialization expertise will expedite their shared mission of delivering pozdeutinurad’s potentially transformative benefits to individuals living with gout.

Source: https://www.contractpharma.com/breaking-news/sobi-agrees-to-acquire-arthrosi-therapeutics/